---
document_datetime: 2023-09-21 18:29:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/budesonideformoterol-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: budesonideformoterol-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1724196
conversion_datetime: 2025-12-25 03:05:47.799546
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Budesonide/Formoterol Teva

Procedural steps taken and scientific information after the authorisation

<!-- image -->

<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A31/0002             | Pursuant to Article 31 of Directive 2001/83/EC, the European Commission initiated a procedure on 27 April 2015 further to concerns over the risk of pneumonia in patients with chronic obstructive pulmonary disease when treated with inhaled corticosteroids containing medicinal products. The PRAC was requested to assess the impact thereof on the benefit-risk balance of inhaled corticosteroids containing medicinal products and to give its | 28/04/2016 product                  | 06/07/2016                                     | SmPC and PL                      | Please refer to the assessment report: Inhaled corticosteroids containing products indicated in the treatment of chronic obstructive pulmonary disease- EMEA/H/A-31/1415 |

Medicinal product no longer authorised

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | recommendation whether the marketing authorisation of these products should be maintained, varied, suspended or revoked.                                                                                                                                                                                                                                                                   |                    |            |                                  |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|----------------------------------|-----------------------------------|
| IB/0008/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including | 14/06/2016         | n/a        | longer                           | authorised                        |
| PSUSA/10202 /201510 | replacement or addition) Periodic Safety Update EU Single assessment - BUDESONIDE, FORMOTEROL                                                                                                                                                                                                                                                                                              | 13/05/2016         | n/a no     |                                  | PRAC Recommendation - maintenance |
| IB/0007             | B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                                                                       | 22/04/2016 product | n/a        |                                  |                                   |
| PSUSA/10202 /201504 | Periodic Safety Update EU Single assessment - BUDESONIDE, FORMOTEROL FUMARATE DIHYDRATE                                                                                                                                                                                                                                                                                                    | 06/11/2015         | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0005/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other Medicinal                                                                                                                                      | 17/09/2015         | 06/07/2016 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------|
| IA/0003/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                | 24/07/2015 | n/a authorised |
| II/0001/G | procedure This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal product | 26/03/2015 | n/a no longer  |